1. Home
  2. CPAY vs RPRX Comparison

CPAY vs RPRX Comparison

Compare CPAY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corpay Inc.

CPAY

Corpay Inc.

HOLD

Current Price

$364.70

Market Cap

23.3B

Sector

Technology

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$55.95

Market Cap

25.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPAY
RPRX
Founded
1986
1996
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.3B
25.2B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
CPAY
RPRX
Price
$364.70
$55.95
Analyst Decision
Buy
Strong Buy
Analyst Count
11
5
Target Price
$382.64
$51.40
AVG Volume (30 Days)
627.1K
3.2M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
1.90%
EPS Growth
7.59
N/A
EPS
5.07
0.67
Revenue
$4,528,403,000.00
$2,378,193,000.00
Revenue This Year
$18.65
$38.63
Revenue Next Year
$10.46
$4.73
P/E Ratio
$70.30
$83.11
Revenue Growth
13.93
5.06
52 Week Low
$252.84
$34.63
52 Week High
$367.43
$58.84

Technical Indicators

Market Signals
Indicator
CPAY
RPRX
Relative Strength Index (RSI) 59.58 52.45
Support Level $317.05 $38.07
Resistance Level N/A $56.50
Average True Range (ATR) 11.15 1.31
MACD 1.74 -0.17
Stochastic Oscillator 86.20 48.95

Price Performance

Historical Comparison
CPAY
RPRX

About CPAY Corpay Inc.

Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. The company offers payment and spend management solutions, including accounts payable automation, cross-border payments, commercial card programs, vehicle payment solutions, and lodging payment services. Its reportable segments are: Corporate Payments, Vehicle Payments, Lodging Payments and Other. The majority of the company's revenue is derived from the Vehicle Payments segment, which helps customers to pay for vehicle related expenses. Geographically, it derives the maximum revenue from the United States and the rest from Brazil, the United Kingdom and other countries.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: